Group 1 - The company Daosheng Tianhe (601026.SH) is listed today [1] - The company Bibet (688759.SH) is open for subscription [1]

投资者请按此价格在2025年10月17日（T日）进行网上和网下申购，申购时无需缴付申购资金。其中， 网下申购时间为09:30-15:00，网上申购时间为09:30-11:30，13:00-15:00。 格隆汇10月15日丨必贝特(688759.SH)公布，发行人和主承销商根据初步询价结果，综合评估公司合理 投资价值、可比上市公司估值水平、所属行业二级市场估值水平等方面，充分考虑网下投资者有效申购 倍数、市场情况、募集资金需求及承销风险等因素，协商确定本次发行价格为17.78元/股，网下发行不 再进行累计投标询价。 ...

Group 1 - Four companies, He Yuan Bio (688765.SH), Biobetter (688759.SH), Xi'an Yichai (688783.SH), and Taikai Ying (920020.BJ), were listed today [1] - Two companies, Delijia (603092.SH) and Zhongcheng Consulting (920003.BJ), are open for subscription [1]

Core Viewpoint - The company Bibeite (688759.SH) has initiated its subscription with an issue price of 17.78 yuan per share, focusing on innovative drug development in the biopharmaceutical sector, particularly targeting major diseases such as tumors and autoimmune diseases [1] Group 1: Company Overview - Bibeite is a biopharmaceutical company that emphasizes clinical value and is dedicated to the independent research and development of innovative drugs [1] - The company has one approved breakthrough therapy drug, BEBT-908, for the treatment of r/rDLBCL, and several other products in various stages of clinical trials [1] - BEBT-908 is the first-in-class small molecule dual-target inhibitor designed for HDAC/PI3Kα, with no other similar inhibitors approved or in development in China as of June 30, 2025 [1] Group 2: Financial Performance - For the fiscal years 2022, 2023, and 2024, the company's net profits are projected to be approximately -188 million yuan, -173 million yuan, and -55.998 million yuan respectively [2] - The company is currently not profitable and anticipates significant ongoing R&D investments, which will keep R&D expenses at a high level [2] - Due to the lack of profitability, the company may not be able to distribute profits or pay cash dividends in the short term [2]

- The report tracks the recent IPO market performance, focusing on the net gains from new stock listings across the Sci-Tech Innovation Board, ChiNext, and Main Board, assuming all stocks are successfully subscribed and sold at the market average price on the first trading day, excluding lock-up restrictions[1][11][39] - The cumulative IPO net gains for A-class accounts with a scale of 2 billion reached 2.44%, while B-class accounts of the same scale achieved 2.19% as of October 24, 2025[11][39] - For larger accounts with a scale of 10 billion, the IPO net gains were significantly lower, with A-class accounts at 0.77% and B-class accounts at 0.70%[11][39] - The average first-day price increase for Sci-Tech Innovation Board stocks was 218.45%, while ChiNext stocks saw an average increase of 244.28%[1][16] - The report provides detailed calculations for theoretical IPO gains, using formulas such as: $ Full subscription quantity = Maximum subscription limit × Average offline subscription rate $ $ Full subscription gains = (First-day average price - IPO price) × Full subscription quantity $[35][39] - The highest full subscription gains among recent IPOs were achieved by United Power, Jindal Zhixin, and C Marco, with gains of 50.81, 12.58, and 11.03 million yuan respectively[35][38] - The report also includes monthly tracking of IPO gains for A-class accounts across different scales, showing a cumulative gain rate of 6.17% for 2 billion accounts since 2024, and 2.44% for 2025 alone[39][41] - Similar tracking for B-class accounts reveals a cumulative gain rate of 5.11% for 2 billion accounts since 2024, and 2.19% for 2025 alone[47][45] - The report highlights the IPO subscription process, including strategic placement, offline inquiry, and online pricing methods, with detailed statistics on subscription rates, oversubscription multiples, and effective subscription ratios for recent IPOs like Xi'an Yicai and Bibet[24][25]

Core Points - Three companies, Bibit (688759.SH), Heyuan Bio (688765.SH), and Xi'an Yicai (688783.SH), are set to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, marking the first batch of new listings since the launch of the Sci-Tech Growth Tier [1] - As of now, a total of 7.58 million investor accounts have opened trading permissions for the Sci-Tech Growth Tier, representing 126% of the active accounts among existing investors [1] - Following the release of the "1+6" policy reform for the Sci-Tech Board in June, 26 new companies have been accepted for listing, with 8 of them being unprofitable [1] - The first IPO application under the fifth set of listing standards, submitted by professional institutional investor Tianomaibo, was accepted on July 31 [1] - On September 26, the second IPO project under the restarted fifth set of listing standards, Anshi Bio, was accepted [1] - Companies such as Beixin Life, unprofitable company Moer Thread, and Angrui Micro have submitted registration on July 25, September 26, and October 15, respectively, under the fifth set of standards [1] - Unprofitable company Muxi Co. passed the listing committee review on October 24 [1]

Group 1: New Stock Performance - Two new stocks were listed last week (October 20-24), with an average first-day price increase of 263.20%[2] - Both new stocks had first-day gains exceeding 100%, specifically Chao Ying Electronics at 397.60% and Marco Polo at 128.80%[2][4] - The total fundraising amount for new stocks last week increased by 1.591 billion yuan compared to the previous week[3] Group 2: Weekly and Monthly Trends - The number of new stocks listed remained unchanged at 2 for the week of October 20-24, with no first-day price drops recorded[3] - For the week of October 13-17, the average first-day price increase was 325.18%, with two stocks showing gains over 100%[4] - Monthly data shows that from October 1 to October 24, 5 new stocks were listed, raising 3.653 billion yuan, with an average first-day increase of 305.31%[10]

广州必贝特医药股份有限公司 首次公开发行股票科创板 上市公告书提示性公告 保荐人（主承销商）：中信证券股份有限公司 联席主承销商：国信证券股份有限公司 扫描二维码查阅公告全文 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、 完整、及时，没有虚假记载、误导性陈述或重大遗漏。 经上海证券交易所审核同意，广州必贝特医药股份有限公司（以下简称"必 贝特"、"公司"、"本公司"或"发行人"）发行的人民币普通股股票将于 2025 年 10 月 28 日在上海证券交易所科创板上市，上市公告书全文和首次公开发行股 票的招股说明书在上海证券交易所网站（http://www.sse.com.cn）和符合中国证 监会规定条件网站（上海证券报：https://www.cnstock.com；中国证券报： https://www.cs.com.cn/ ；证券日报： http://www.zqrb.cn ； 证 券 时 报 ： https://www.stcn.com ； 经 济 参 考 报 ： http://www.jjckb.cn ； 金 融 时 报 ： https://www.financialnews.com ...

股票简称：必贝特 股票代码：688759 广州必贝特医药股份有限公司 BeBetter Med Inc. （住所：广州市高新技术产业开发区科学城崖鹰石路 25 号 A-3 栋第 八层 802 房） 首次公开发行股票科创板上市公告书 保荐人（主承销商） （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 联席主承销商 （深圳市罗湖区红岭中路 1012 号国信证券大厦十六层至二十六层） 二〇二五年十月 广州必贝特医药股份有限公司（以下简称"必贝特"、"本公司"、"发行 人"、"公司"）股票将于 2025 年 10 月 28 日在上海证券交易所科创板上市。 根据《上海证券交易所科创板上市公司自律监管指引第 5 号——科创成长 层》，上市时未盈利的科创板公司，自上市之日起纳入科创成长层。截至本公告 披露日，必贝特尚未盈利，自上市之日起将纳入科创成长层。 普通投资者参与科创成长层股票或者存托凭证交易的，应当符合科创板投资 者适当性管理的要求，并按照上海证券交易所有关规定，在首次参与交易前以纸 面或者电子形式签署《科创成长层风险揭示书》，由证券公司充分告知相关风险。 本公司提醒投资者应充分了解股票市场风险及本 ...

广州必贝特医药股份有限公司 章程(草案) $$\Xi{\bf{\cal{O}}}\,{\bf{\underline{{{--}}}}}\,\nexleftarrow\nexists\,\nexists\,\exists\,{\bf{\cal{H}}}$$ and and of the same | 第一章 总则 | | --- | | 第二章 经营宗旨和范围 | | 第三章 取り | | 第一节 股份发行 . | | 第二节 股份增减和回购 | | 第三节 股份转让 . | | 第四章 股东和股东大会 | | 第一节 股东 . | | 第二节 股东大会的一般规定 | | 第三节 股东大会的召集 | | 第四节 股东大会的提案与通知 . | | 第五节 股东大会的召开 . | | 第六节 股东大会的表决和决议 . | | 第五章 董事会 ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 28 | | 第一节 董事 . | | 第二节 董事会 | ...